Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells

Veterinary and Comparative Oncology

Volumn 10, Issue 2, 2012, Pages 143-154

  Lawrence, J ^a   Saba, C ^a   Gogal, R ^a   Lamberth, O ^a   Vandenplas, M L ^a   Hurley, D J ^a   Dubreuil, P ^b   Hermine, O ^c   Dobbin, K ^a   Turek, M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b AB Science SA   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Cat; Injection site sarcoma; Masitinib; Platelet derived growth factor receptor; Tyrosine kinase inhibitor; Vaccine associated sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; INACTIVATED VACCINE; MASITINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; THIAZOLE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SARCOMA; SOFT TISSUE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAT DISEASES; CATS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SARCOMA; SOFT TISSUE NEOPLASMS; THIAZOLES; VACCINES, INACTIVATED;

FELIDAE;

EID: 84860343001     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00291.x     Document Type: Article

References (50)

1. Hendrick MJ and Goldschmidt MH. Do injection site reactions induce fibrosarcomas in cats? Journal of the American Veterinary Medical Association 1991; 199: 968.
2. Hendrick MJ, Goldschmidt MH, Schofer FS, Wang YY and Somlyo AP. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Research 1992; 52: 5391-5394.
3. Kass PH, Barnes WG, Spangler WL, Chomel BB and Culbertson MR. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. Journal of the American Veterinary Medical Association 1993; 204: 396-405.
4. th edn., SJ Withrow and DM Vail, eds., 425-454. St. Louis, Saunders Elsevier, 2007.
5. Hendrick MJ, Shofer FS, Goldschmidt MH, Haviland JC, Schelling SH, Engler SJ and Gliatto JM. Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992). Journal of the American Veterinary Medical Association 1994; 205: 1425-1429.
6. Lester S, Clemett T and Burt A. Vaccine-associated sarcomas in cats: clinical experience and a laboratory review (1982-1993). Journal of the American Animal Hospital Association 1996; 32: 91-95.
7. Hendrick MJ, Kass PH, McGill LD and Tizard IR. Postvaccinal sarcomas in cats. Journal of the National Cancer Institute 1994; 86: 341-343.
8. Coyne MJ, Reeves NCP and Rosen DK. Estimated prevalence of injection-site sarcomas in cats during 1992. Journal of the American Veterinary Medical Association 1997; 210: 249-251.
9. Burton G and Mason KV. Do postvaccinal sarcomas occur in Australian cats? Australian Veterinary Journal 1997; 75: 102-106.
10. McEntee MC and Page RL. Feline vaccine-associated sarcomas. Journal of Veterinary Internal Medicine 2001; 15: 176-182.
11. McNiel EA. Vaccine-associated sarcomas in cats: a unique cancer model. Clinical Orthopaedics and Related Research 2001; 382: 21-27.
12. Hendrick MJ. Feline vaccine-associated sarcomas: current studies on pathogenesis. Journal of the American Veterinary Medical Association 1998; 213: 1425-1426.
13. Morrison WB, Starr RM and VAFSTF. Vaccine-associated feline sarcomas. Journal of the American Veterinary Medical Association 2001; 218: 697-702.
14. Morrison WB and Sarr RM. Vaccine-associated feline sarcomas. Journal of Veterinary Diagnostic Investigation 2001; 5: 697-702.
15. Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS and Vail DM. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). Journal of the American Veterinary Medical Association 2000; 216: 58-61.
16. Cronin K, Page RL, Spodnik G, Dodge R, Hardie EN, Price GS, Ruslander D and Thrall DE. Radiation therapy and surgery for fibrosarcoma in 33 cats. Veterinary Radiology and Ultrasound 1998; 39: 51-56.
17. Bregazzi VS, LaRue SM, McNiel E, Macy DW, Dernell WS, Powers BE and Withrow SJ. Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats with vaccine associated sarcomas: 25 cases (1995-2000). Journal of the American Veterinary Medical Association 2001; 218: 547-550.
18. Cohen M, Wright JC, Brawner WR, Smith AN, Henderson R and Behrend EN. Use of surgery and electron beam irradiation, with or without chemotherapy for treatment of vaccine associated sarcomas in cats: 78 cases (1996-2000). Journal of the American Veterinary Medical Association 2001; 219: 1582-1589.
19. Kobayashi T, Hauck M, Hauck ML, Dodge R, Page RL, Price GS, Williams LE, Hardie EM, Mathews KG and Thrall DE. Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Veterinary Radiology and Ultrasound 2002; 43: 473-479.
20. Dillon C, Mauldin G and Baer K. Outcome following surgical removal of nonvisceral soft tissue sarcomas in cats: 42 cases (1992-2000). Journal of the American Veterinary Medical Association 2005; 227: 1955-1957.
21. Eckstein C, Guscetti F, Roos M, Martin de las Mulas J, Kaser-Hotz B and Rohrer Bley C. A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma. Veterinary and Comparative Oncology 2009; 7: 54-68.
22. Poirier VJ, Thamm DH, Kurzman ID, Jeglum KA, Chun R, Obradovich JE, O'Brien M, Fred RM III, Phillips BS and Vail DM. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. Journal of Veterinary Internal Medicine 2002; 16: 726-731.
23. Hahn KA, Endicott MM, King GK and Harris-King FD. Evaluation of radiotherapy alone or in combination with doxorubicin chemotherapy for the treatment of cats with incompletely excised soft tissue sarcomas: 71 cases (1989-1999). Journal of the American Veterinary Medical Association 2007; 231: 742-745.
24. Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH and Vail DM. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemotherapy and Pharmacology 2004; 54: 25-33.
25. Heldin CH and Westermark B. Mechanism of action and in vivo role of platelet derived growth factor. Physiological Reviews 1999; 79: 1283-1316.
26. Heldin CH, Ostman A and Ronstrand L. Signal transduction via platelet-derived growth factor receptors. Biochimica et Biophysica Acta 1998; 1378: F79-F113.
27. Hendrick MJ. Feline vaccine-associated sarcomas. Cancer Investigation 1999; 17: 273-274.
28. Nieto A, Sanchez MA, Martinez E and Rollan E. Immunohistochemical expression of p53, fibroblast growth factor-b, and transforming growth factor-alpha in feline vaccine-associated sarcomas. Veterinary Pathology 2003; 40: 651-658.
29. Smith AJ, Njaa BL and Lamm CG. Immunohistochemical expression of c-KIT protein in feline soft tissue fibrosarcomas. Veterinary Pathology 2009; 46: 934-939.
30. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, LeBlanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A and Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008; 22: 1301-1309.
31. Bellamy F, Bader T, Moussy A and Hermine O. Pharmacokinetics of masitinib in cats. Veterinary Research Communications 2009; 33: 831-837.
32. Debreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, Borge L, Hajem B, Lermet A, Sippl W, Voiseet E, Arock M, Auclair C, Leventhal P, Mansfield CD, Moussy A and Hermine O. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PloS ONE 2009; 4: e7258.
33. Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, Carreras JK, Lana SE, LaDue T, Rusk A, Kinet JP, Dubreuil P, Moussy A and Hermine O. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. American Journal of Veterinary Research 2010; 71: 1354-1361.
34. Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz J, Moussy A, Kinet J, Hermine O, Rougier P and Raymond E. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy Pharmacology 2010; 66: 395-403.
35. Le Cesne A, Blay JY, Bui BN, Bouche O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP and Hermine O. Phase II study of oral masitinib mesilate in imatinib-naÏve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer 2010; 46: 1344-1351.
36. Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmerini F, Mansfield CD, Gineste P, Moussy A, Hermine O and Lortholary O. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. American Journal of Hematology 2010; 85: 921-925.
37. Soria JC, Massard C, Magne N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O and Armand JP. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. European Journal of Cancer 2009; 45: 2333-2341.
38. Humbert M, Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O and Chanez P. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009; 64: 1194-1201.
39. Cadot P, Hensel P, Bensignor E, Hadjaje C, Marignac G, Beco L, Fontaine J, Jamet JF, Georgescu G, Campbell K, Cannon A, Osborn SC, Messinger L, Gogny-Goubert M, Dubreuil P, Moussy A and Hermine O. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Veterinary Dermatology 2011; doi: 10.1111/j.1365-3164.2011.00990.x.
40. Gogal RM Jr, Smith BJ, Kalnitsky J and Holladay SD. Analysis of apoptosis of lymphoid cells in fish exposed to immunotoxic compounds. Cytometry 2000; 39: 310-318.
41. Campbell DJ, Heaton PR, Pritchard DI, Strain JJ, Rawlings JM and Hannigan BM. Assessment of ex vivo responses to T-cell mitogens and oxidative stress in lymphocytes from healthy adult and senior cats. The Journal of Nutrition 2006; 136(Suppl. 7): 2084S-2086S.
42. Schmid I, Uittenbogaart CH and Giorgi JV. Sensitive method of measuring apoptosis and cell surface phenotype in human thymocyte by flow cytometry. Cytometry 1994; 15: 12-20.
43. Schmid I, Uittenbogaart CH, Keld B and Giorgi JV. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. Journal of Immunological Methods 1994; 170: 145-157.
44. Sabbatini S and Bettini G. Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumours. Veterinary Pathology 2010; 47: 643-653.
45. Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, Hermine O and Dubreuil P. Masitinib as a chemosensitizer of canine tumor cell lines: A proof of concept study. The Veterinary Journal 2011; DOI: 10.1016/j.tvjl.2011.01.001.
46. Thamm DH, Huelsmeyer MK, Mitzey AM, Qurollo B, Rose BJ and Kurzman ID. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Research 2010; 20: 35-42.
47. Levine RA. Overexpression of the sis oncogene in a canine osteosarcoma cell line. Veterinary Pathology 2002; 39: 411-412.
48. Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O and Dubreuil P. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE 2010; 5: e9430. DOI: 10.1371/journal.pone.0009430.
49. Knight ZA, Lin H and Shokat KM. Targeting the cancer kinome through polypharmacy. Nature Reviews Cancer 2010; 10: 130-137.
50. Paoloni M and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008; 8: 147-156.